M. Ten Berge
Leiden University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. Ten Berge.
BMJ Quality & Safety | 2013
H.S. Snijders; D. Henneman; N L van Leersum; M. Ten Berge; Marta Fiocco; Tom Karsten; Klaas Havenga; T. Wiggers; J.W.T. Dekker; R.A.E.M. Tollenaar; Michel W.J.M. Wouters
Introduction When comparing mortality rates between hospitals to explore hospital performance, there is an important role for adjustment for differences in case-mix. Identifying outcome measures that are less influenced by differences in case-mix may be valuable. The main goal of this study was to explore whether hospital differences in anastomotic leakage (AL) and postoperative mortality are due to differences in case-mix or to differences in treatment factors. Methods Data of the Dutch Surgical Colorectal Audit were used. Case-mix factors and treatment-related factors were identified from the literature and their association with AL and mortality were analysed with logistic regression. Hospital differences in observed AL and mortality rates, and adjusted rates based on the logistic regression models were shown. The reduction in hospital variance after adjustment was analysed with Levenes test for equality of variances. Results 17 of 22 case-mix factors and 4 of 11 treatment factors related to AL derived from the literature were available in the database. Variation in observed AL rates between hospitals was large with a maximum rate of 17%. This variation could not be attributed to differences in case-mix but more to differences in treatment factors. Hospital variation in observed mortality rates was significantly reduced after adjustment for differences in case-mix. Conclusions Hospital variation in AL is relatively independent of differences in case-mix. In contrast to ‘postoperative mortality’ the observed AL rates of hospitals evaluated in our study were only slightly affected after adjustment for case-mix factors. Therefore, AL rates may be suitable as an outcome indicator for measurement of surgical quality of care.
Clinical Oncology | 2017
Iris Walraven; R. Damhuis; M. Ten Berge; Michael Rosskamp; L. van Eycken; Dirk De Ruysscher; J. Belderbos
AIMS Concurrent chemoradiotherapy (CCRT) is considered the standard treatment regimen in non-surgical locally advanced non-small cell lung cancer (NSCLC) patients and sequential chemoradiotherapy (SCRT) is recommended in patients who are unfit to receive CCRT or when the treatment volume is considered too large. In this study, we investigated the proportion of CCRT/SCRT in the Netherlands and Belgium. Furthermore, patient and disease characteristics associated with SCRT were assessed. MATERIALS AND METHODS An observational study was carried out with data from three independent national registries: the Belgian Cancer Registry (BCR), the Netherlands Cancer Registry (NCR) and the Dutch Lung Cancer Audit-Radiotherapy (DLCA-R). Differences in patient and disease characteristics between CCRT and SCRT were tested with unpaired t-tests (for continuous variables) and with chi-square tests (for categorical variables). A prognostic model was constructed to determine patient and disease parameters predictive for the choice of SCRT. RESULTS This study included 350 patients from the BCR, 780 patients from the NCR and 428 patients from the DLCA-R. More than half of the stage III NSCLC patients in the Netherlands (55%) and in Belgium more than a third (35%) were treated with CCRT. In both the Dutch and Belgian population, higher age and more advanced N-stage were significantly associated with SCRT. Performance score, pulmonary function, comorbidities and tumour volume were not associated with SCRT. CONCLUSION In this observational population-based study, a large treatment variation in non-surgical stage III NSCLC patients was observed between and within the Netherlands and Belgium. Higher age and N-stage were significantly associated with the choice for SCRT.
Ejso | 2013
N.J. van Leersum; H.S. Snijders; D. Henneman; Nikki E. Kolfschoten; G.A. Gooiker; M. Ten Berge; E.H. Eddes; Michel W.J.M. Wouters; Rob A. E. M. Tollenaar; Willem A. Bemelman; R.M. van Dam; M.A.G. Elferink; Th.M. Karsten; J.H.J.M. van Krieken; V.E.P.P. Lemmens; H.J.T. Rutten; Eric R. Manusama; C.J.H. van de Velde; W.J.H.J. Meijerink; T. Wiggers; E. van der Harst; J.W.T. Dekker; Djamila Boerma
Annals of Surgical Oncology | 2013
D. Henneman; N.J. van Leersum; M. Ten Berge; H.S. Snijders; Marta Fiocco; T. Wiggers; R.A.E.M. Tollenaar; Michel W.J.M. Wouters
Journal of The National Comprehensive Cancer Network | 2015
Lieke Gietelink; M.W.J.M. Wouters; P. J. Tanis; M.M. Deken; M. Ten Berge; R.A.E.M. Tollenaar; J.H.J.M. van Krieken; M.E. de Noo
Journal of Thoracic Oncology | 2015
Iris Walraven; M. Ten Berge; R. Damhuis; C. Tissing-Tan; E.G.C. Troost; Bart Reymen; Joachim Widder; F. Koppe; A. Van der Wel; E. Vonk; I. Coremans; J. Bussink; K. De Jaeger; N. Van der Voort Van Zyp; Sherif Y. El Sharouni; H. Knol; D. Woutersen; J. Belderbos
Journal of Thoracic Oncology | 2015
J. Belderbos; E.G.C. Troost; M. Ten Berge; Iris Walraven; Bart Reymen; C. Tissing-Tan; Joachim Widder; F. Koppe; E. Vonik; I. Coremans; J. Bussink; K. De Jaeger; N. Van der Voort Van Zyp; S. Y. El Sharouni; H. Knol; J. Peer-Valstar; A. Van der Wel
Journal of Thoracic Oncology | 2015
J. Belderbos; E.G.C. Troost; M. Ten Berge; Iris Walraven; Bart Reymen; C. Tissing-Tan; Joachim Widder; F. Koppe; E. Vonik; I. Coremans; J. Bussink; K. De Jaeger; N. Van der Voort Van Zyp; S. Y. El Sharouni; H. Knol; J. Peer-Valstar; A. Van der Wel
Nederlands Tijdschrift voor Oncologie | 2014
D. Henneman; M. Ten Berge; C.G. Verhoef; M.J.M. Ploegmakers; J. Bussink; C. Tissing-Tan; E. Vonk; A. Van der Wel; M. Verheij; A. Dekker; J. Belderbos
Ejso | 2014
M. Ten Berge; Vincent B. Ho; O. Visster; R.A.E.M. Tollenaar; M.W.J.M. Wouters